FULC
Fulcrum Therapeutics, Inc.
$6.47
+1.89%
$423.0M
No data for this timeframe.
Vol
Market Cap$423.0M
Cap SizeSmall Cap
Inst. Holders7 funds
Inst. Value$51.3M
Inst. Activity2 buys / 2 sells
Insider Activity0B / 2S
Insider Net $-$323.9K
SEC Reports2
Press Releases1
Recent Activity
May 8, 2026
other
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>CAMBRIDGE, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.<sup>®</sup> (Nasd
Apr 27, 2026
SEC
Fulcrum Therapeutics terminated a license agreement for its Diamond-Blackfan anemia program, reported Q1 2026 earnings w
8-K — Impact 6/10
Apr 27, 2026
SEC
Fulcrum Therapeutics reported a net loss of $18.9 million for Q1 2026 with EPS of $-0.25, narrowly missing consensus EPS
PRESS-RELEASE — Impact 6/10
Apr 23, 2026
Insider
Lehrer-Graiwer Joshua sold 64,000 shares
Director @ $0.00 ($0.00)
Feb 2, 2026
Insider
Musso Alan A sold 170,000 shares
Chief Financial Officer @ $0.00 ($0.00)
Feb 2, 2026
Insider
Oltmans Curtis Gale sold 170,000 shares
Chief Legal Officer @ $0.00 ($0.00)
Inst.
BANK OF AMERICA CORP — ADD
231,177 shares ($2.6M)
Inst.
WELLS FARGO & COMPANY/MN — DOUBLED
166,395 shares ($1.9M)
Price Targets
Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$18.90 (Jan 2026)
Current $6.47
Low $8.00
Median $20.50
High $25.00
10 analysts
$8.00
$25.00
Analyst Ratings
5Strong Buy
8Buy
2Hold
1Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jan 12, 2026 | JP Morgan | INITIATE | Overweight |
| Dec 11, 2025 | Truist Securities | MAINTAIN | Buy → Buy |
| Dec 9, 2025 | B of A Securities | MAINTAIN | Underperform → Underperform |
| Dec 8, 2025 | RBC Capital | MAINTAIN | Sector Perform → Sector Perform |
| Dec 8, 2025 | Cantor Fitzgerald | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.28 ▲ +10.4% | $-0.35 — $-0.24 | -0% YoY | 11 |
| Next Q | $-0.31 ▲ +7.2% | $-0.46 — $-0.26 | -0% YoY | 11 |
| Current FY | $-1.17 ▲ +10.0% | $-1.55 — $-1.03 | 1% YoY | 11 |
| Next FY | $-1.33 ▲ +17.2% | $-1.91 — $-0.91 | -14% YoY | 11 |
Latest Reports
MIXED
8-K
6/10
Fulcrum Therapeutics terminated a license agreement for its Diamond-Blackfan anemia program, reported Q1 2026 earnings w
Apr 27, 2026
MIXED
PRESS-RELEASE
6/10
Fulcrum Therapeutics reported a net loss of $18.9 million for Q1 2026 with EPS of $-0.25, narrowly missing consensus EPS
Apr 27, 2026
NEUTRAL
Press
3/10
Fulcrum Therapeutics (FULC) announced a partnership with MedicAlert Foundation and the Sickle Cell Disease Association o
Mar 19, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $40.3M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $4.4M | TRIM |
| BANK OF AMERICA CORP | $2.6M | ADD |
| WELLS FARGO & COMPANY/MN | $1.9M | DOUBLED |
| MORGAN STANLEY | $1.9M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 23, 2026 | Lehrer-Graiwer Joshua | A | $0.00 |
| Feb 2, 2026 | Musso Alan | A | $0.00 |
| Feb 2, 2026 | Oltmans Curtis | A | $0.00 |
| Feb 2, 2026 | Tourangeau Greg | A | $0.00 |
| Feb 2, 2026 | Sapir Alex | A | $0.00 |
7 institutional holders with $51.3M total value (4,536,734 shares) as of 2025-Q4. Top holders: VANGUARD, CHARLES, BANK.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 3,559,552 | $40.3M | 78.5% | — |
| 2 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 388,896 | $4.4M | 8.6% | TRIM -27.5% |
| 3 | BANK OF AMERICA CORP /DE/ | 231,177 | $2.6M | 5.1% | ADD +57.0% |
| 4 | WELLS FARGO & COMPANY/MN | 166,395 | $1.9M | 3.7% | DOUBLED +411.9% |
| 5 | MORGAN STANLEY | 165,623 | $1.9M | 3.7% | TRIM -32.1% |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 17,400 | $196.8K | 0.4% | NEAR_EXIT -93.0% |
| 7 | FMR LLC | 7,691 | $87.0K | 0.2% | ADD +61.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | ADD | 147,211 | 231,177 | +57.0% | $2.6M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 32,507 | 166,395 | +411.9% | $1.9M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 243,835 | 165,623 | -32.1% | $1.9M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 248,200 | 17,400 | -93.0% | $196.8K | 2025-Q4 |
| UBS Group AG | DOUBLED | 135,205 | 301,157 | +122.7% | $2.8M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 78,500 | 248,200 | +216.2% | $2.3M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 45,989 | 147,211 | +220.1% | $1.4M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 58,965 | 0 | -100.0% | $0.00 | 2025-Q3 |
| UBS Group AG | ADD | 71,920 | 135,205 | +88.0% | $930.2K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 401,100 | 78,500 | -80.4% | $540.1K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 150,274 | 58,965 | -60.8% | $405.7K | 2025-Q2 |
| FMR LLC | ADD | 4,318 | 6,967 | +61.3% | $47.9K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 401,100 | — | $1.2M | 2025-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | TRIM | 526,045 | 381,359 | -27.5% | $1.1M | 2025-Q1 |
| MORGAN STANLEY | NEAR_EXIT | 1,531,732 | 285,599 | -81.4% | $822.5K | 2025-Q1 |
| FMR LLC | NEAR_EXIT | 90,465 | 4,318 | -95.2% | $12.4K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 350,685 | 1,531,732 | +336.8% | $7.2M | 2024-Q4 |
| CITADEL ADVISORS LLC | TRIM | 1,745,993 | 474,723 | -72.8% | $2.2M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 25,503 | 34,264 | +34.4% | $161.0K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 569,185 | — | $2.0M | 2024-Q3 |
| MORGAN STANLEY | TRIM | 1,234,813 | 350,685 | -71.6% | $1.3M | 2024-Q3 |
6 unique insiders with 2 transactions. Net insider value: -$323.9K ($0.00 bought, $323.9K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 23, 2026 | Lehrer-Graiwer Joshua | Director | A | 64,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Musso Alan A | Chief Financial Officer | A | 170,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Oltmans Curtis Gale | Chief Legal Officer | A | 170,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Tourangeau Greg | Principal Accounting Officer | A | 57,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Sapir Alex | See Remarks | A | 650,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Gould Robert J | Director | SELL | 15,000 | $10.72 | $160.9K |
| Jan 2, 2026 | Gould Robert J | Director | SELL | 15,000 | $10.87 | $163.1K |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 2 mixed, 0 neutral. Avg impact: 6.0/10.
Historical analyst distribution (last covering-analyst action Jan 2026): 81% buy across 16 analysts — 5 strong buy, 8 buy, 2 hold, 1 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$18.90 mean target (Jan 2026)
$8.00 Low
$25.00 High
| Metric | Value |
|---|---|
| Current Price | $6.47 |
| Target Low | $8.00 |
| Target Mean | $18.90 |
| Target Median | $20.50 |
| Target High | $25.00 |
| # Analysts | 10 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.28 | $-0.35 | $-0.24 | -0.5% | +10.4% | 8↑ 2↓ | $0.0B | 0.0% | 11 |
| Next Q 2026-09-30 |
$-0.31 | $-0.46 | $-0.26 | -0.4% | +7.2% | 7↑ 3↓ | $0.0B | 0.0% | 11 |
| Current FY 2026-12-31 |
$-1.17 | $-1.55 | $-1.03 | 0.8% | +10.0% | 8↑ 2↓ | $0.0B | 0.0% | 11 |
| Next FY 2027-12-31 |
$-1.33 | $-1.91 | $-0.91 | -13.5% | +17.2% | 8↑ 1↓ | $0.0B | 0.0% | 11 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.281 | |
| 7d ago | $-0.286 | +0.005 |
| 30d ago | $-0.314 | +0.033 |
| 60d ago | $-0.314 | +0.033 |
| 90d ago | $-0.296 | +0.015 |
7 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jan 12, 2026 | JP Morgan | INITIATE | — | Overweight |
| Dec 11, 2025 | Truist Securities | MAINTAIN | Buy | Buy |
| Dec 9, 2025 | B of A Securities | MAINTAIN | Underperform | Underperform |
| Dec 8, 2025 | RBC Capital | MAINTAIN | Sector Perform | Sector Perform |
| Dec 8, 2025 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Dec 8, 2025 | Piper Sandler | REITERATE | Overweight | Overweight |
| Dec 8, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Nov 24, 2025 | Truist Securities | INITIATE | — | Buy |
| Nov 24, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 5 | 8 | 2 | 1 | 0 | 81% | |
| Apr 1, 2026 | 5 | 8 | 2 | 1 | 0 | 81% | |
| Mar 1, 2026 | 5 | 8 | 2 | 1 | 0 | 81% | |
| Feb 1, 2026 | 5 | 8 | 2 | 1 | 0 | 81% | |
| Jan 1, 2026 | 5 | 7 | 2 | 1 | 0 | 80% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 8, 2026
other
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>CAMBRIDGE, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.<sup>®</sup> (Nasdaq: FULC), a clinical-stage biopharmaceutical comp
Apr 27, 2026
earnings
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
<p align="center"><em>― Presented positive clinical data for pociredir, demonstrating robust and rapid fetal hemoglobin (HbF) induction, improvements
Apr 27, 2026
other
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
<p>CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.<sup>® </sup>(Fulcrum) (NASDAQ: FULC), a clinical-stage biopharmac
Apr 27, 2026
earnings_calendar
FULC Q1 2026 Earnings Scheduled — 2026-04-27
Mar 19, 2026
contract
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease
Three-year collaboration is aimed at enhancing a key aspect of sickle cell management: expediting care during a pain crisis <pre>Three-year collaborat
Mar 6, 2026
other
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focus
Mar 3, 2026
other
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
<p>CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.<sup>®</sup> (the “Company”) (Nasdaq: FULC), a clinical-stage biop
Feb 24, 2026
earnings_calendar
FULC Q4 2025 Earnings After Market Close — 2026-02-24